Table 1.
Baseline clinical parameters
| All patients (n = 42) | Cardiac sarcoidosis (n = 13) | Not cardiac sarcoidosis (n = 29) | P value | |
|---|---|---|---|---|
| Age, year | 53 ± 13 | 59 ± 11 | 50 ± 14 | 0.039 |
| Women, n (%) | 14 (33%) | 4 (31%) | 10 (34%) | 0.99 |
| Body surface area, m2 | 2.0 ± 0.2 | 2.0 ± 0.2 | 2.0 ± 0.2 | 0.30 |
| Systolic blood pressure, mmHg | 124 ± 19 | 129 ± 23 | 121 ± 17 | 0.24 |
| Diastolic blood pressure, mmHg | 75 ± 10 | 79 ± 10 | 74 ± 10 | 0.20 |
| Symptomatic, n (%) | 24 (57%) | 10 (77%) | 14 (48%) | 0.10 |
| Final diagnosis | ||||
| Cardiac sarcoidosis | 13 (31%) | 13 (100%) | – | |
| Extra-cardiac sarcoidosis with no cardiac involvement | 10 (24%) | – | 10 (34%) | |
| Myocarditis | 7 (17%) | – | 7 (24%) | |
| Non-ischemic/inflammatory cardiomyopathy | 12 (29%) | – | 12 (41%) | |
| Risk factors | ||||
| Smoking history, n (%) | 14 (33%) | 7 (54%) | 7 (24%) | 0.08 |
| Hypertension, n (%) | 19 (45%) | 7 (54%) | 12 (41%) | 0.52 |
| Diabetes mellitus, n (%) | 10 (24%) | 2 (15%) | 8 (28%) | 0.47 |
| Hypercholesterolemia, n (%) | 18 (43%) | 7 (54%) | 11 (38%) | 0.50 |
| Medications | ||||
| Beta blocker, n (%) | 22 (53%) | 7 (54%) | 15 (52%) | 0.99 |
| ACE inhibitor, n (%) | 12 (29%) | 4 (31%) | 8 (28%) | 0.99 |
| ARB, n (%) | 6 (14%) | 2 (15%) | 4 (14%) | 0.99 |
| Immune suppression therapy, n (%) | 6 (14%) | 2 (15%) | 4 (14%) | 0.99 |
| Corticosteroids, n (%) | 6 (14%) | 2 (15%) | 4 (14%) | 0.99 |
| Methotrexate, n (%) | 2 (5%) | 1 (8%) | 1 (3%) | 0.53 |
Variables are presented as mean ± standard deviation or number with percentage in parentheses. P values are for the comparison between patients with cardiac sarcoidosis and those without. Final diagnosis of cardiac sarcoidosis was established using modified 2006 revised Japanese Ministry of Health and Welfare (JMHW) guideline as the reference standard
ACE angiotensin-converting enzyme, ARB angiotensin II receptor blockers